Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders: A Mendelian Randomization Study.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 05 2022
Historique:
pubmed: 31 3 2022
medline: 7 5 2022
entrez: 30 3 2022
Statut: ppublish

Résumé

Previous in vitro and postmortem research suggests that inflammation may lead to structural brain changes via activation of microglia and/or astrocytic dysfunction in a range of neuropsychiatric disorders. To investigate the relationship between inflammation and changes in brain structures in vivo and to explore a transcriptome-driven functional basis with relevance to mental illness. This study used multistage linked analyses, including mendelian randomization (MR), gene expression correlation, and connectivity analyses. A total of 20 688 participants in the UK Biobank, which includes clinical, genomic, and neuroimaging data, and 6 postmortem brains from neurotypical individuals in the Allen Human Brain Atlas (AHBA), including RNA microarray data. Data were extracted in February 2021 and analyzed between March and October 2021. Genetic variants regulating levels and activity of circulating interleukin 1 (IL-1), IL-2, IL-6, C-reactive protein (CRP), and brain-derived neurotrophic factor (BDNF) were used as exposures in MR analyses. Brain imaging measures, including gray matter volume (GMV) and cortical thickness (CT), were used as outcomes. Associations were considered significant at a multiple testing-corrected threshold of P < 1.1 × 10-4. Differential gene expression in AHBA data was modeled in brain regions mapped to areas significant in MR analyses; genes were tested for biological and disease overrepresentation in annotation databases and for connectivity in protein-protein interaction networks. Of 20 688 participants in the UK Biobank sample, 10 828 (52.3%) were female, and the mean (SD) age was 55.5 (7.5) years. In the UK Biobank sample, genetically predicted levels of IL-6 were associated with GMV in the middle temporal cortex (z score, 5.76; P = 8.39 × 10-9), inferior temporal (z score, 3.38; P = 7.20 × 10-5), fusiform (z score, 4.70; P = 2.60 × 10-7), and frontal (z score, -3.59; P = 3.30 × 10-5) cortex together with CT in the superior frontal region (z score, -5.11; P = 3.22 × 10-7). No significant associations were found for IL-1, IL-2, CRP, or BDNF after correction for multiple comparison. In the AHBA sample, 5 of 6 participants (83%) were male, and the mean (SD) age was 42.5 (13.4) years. Brain-wide coexpression analysis showed a highly interconnected network of genes preferentially expressed in the middle temporal gyrus (MTG), which further formed a highly connected protein-protein interaction network with IL-6 (enrichment test of expected vs observed network given the prevalence and degree of interactions in the STRING database: 43 nodes/30 edges observed vs 8 edges expected; mean node degree, 1.4; genome-wide significance, P = 4.54 × 10-9). MTG differentially expressed genes that were functionally enriched for biological processes in schizophrenia, autism spectrum disorder, and epilepsy. In this study, genetically determined IL-6 was associated with brain structure and potentially affects areas implicated in developmental neuropsychiatric disorders, including schizophrenia and autism.

Identifiants

pubmed: 35353173
pii: 2790722
doi: 10.1001/jamapsychiatry.2022.0407
pmc: PMC8968718
doi:

Substances chimiques

Brain-Derived Neurotrophic Factor 0
Interleukin-1 0
Interleukin-2 0
Interleukin-6 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

498-507

Subventions

Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S003991/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204623/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N029488/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S037675/1
Pays : United Kingdom

Investigateurs

Jack C Rogers (JC)
Valeria Mondelli (V)
Paola Dazzan (P)
Carmine Pariante (C)
James MacCabe (J)
Alice Egerton (A)
Peter Jones (P)
Ed Bullmore (E)
Nikos Koutsouleris (N)
Eva Meisenzahl (E)
David Cotter (D)
Neil Harrison (N)

Auteurs

John A Williams (JA)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom.
Institute for Translational Medicine, University of Birmingham, Birmingham, United Kingdom.
Health Data Research UK (HRD), Midlands Site, Birmingham, United Kingdom.

Stephen Burgess (S)

Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, United Kingdom.
Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.

John Suckling (J)

Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.

Paris Alexandros Lalousis (PA)

Institute for Mental Health, University of Birmingham, Birmingham, United Kingdom.
Centre for Human Brain Health, University of Birmingham, Birmingham, United Kingdom.

Fatima Batool (F)

Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, United Kingdom.

Sian Lowri Griffiths (SL)

Institute for Mental Health, University of Birmingham, Birmingham, United Kingdom.
Centre for Human Brain Health, University of Birmingham, Birmingham, United Kingdom.

Edward Palmer (E)

Institute for Mental Health, University of Birmingham, Birmingham, United Kingdom.

Andreas Karwath (A)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom.
Institute for Translational Medicine, University of Birmingham, Birmingham, United Kingdom.
Health Data Research UK (HRD), Midlands Site, Birmingham, United Kingdom.

Andrey Barsky (A)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom.
Institute for Translational Medicine, University of Birmingham, Birmingham, United Kingdom.

Georgios V Gkoutos (GV)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom.
Institute for Translational Medicine, University of Birmingham, Birmingham, United Kingdom.
Health Data Research UK (HRD), Midlands Site, Birmingham, United Kingdom.

Stephen Wood (S)

Institute for Mental Health, University of Birmingham, Birmingham, United Kingdom.
Centre for Human Brain Health, University of Birmingham, Birmingham, United Kingdom.
Orygen, Melbourne, Australia.
Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.

Nicholas M Barnes (NM)

Institute for Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.

Anthony S David (AS)

Institute of Mental Health, University College London, London, United Kingdom.

Gary Donohoe (G)

School of Psychology, National University of Ireland Galway, Galway, Ireland.
Centre for Neuroimaging, Cognition and Genomics, National University of Ireland Galway, Galway, Ireland.

Joanna C Neill (JC)

Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Bill Deakin (B)

Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Golam M Khandaker (GM)

Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.
MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, United Kingdom.
NIHR Bristol Biomedical Research Centre, Bristol, United Kingdom.

Rachel Upthegrove (R)

Institute for Mental Health, University of Birmingham, Birmingham, United Kingdom.
Centre for Human Brain Health, University of Birmingham, Birmingham, United Kingdom.
Early Intervention Service, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH